Melorem

Meloxicam, the active ingredient in Melorem, is a nonsteroidal anti-inflammatory drug (NSAID) presented as an oral dosage form for systemic use. It is indicated for the management of inflammatory joint conditions and acute pain in adult patients. GNH USA supplies Melorem as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Meloxicam is employed to control inflammation and pain in several musculoskeletal disorders. - Rheumatoid arthritis: reduces joint swelling, pain and stiffness, helping maintain functional ability. - Osteoarthritis: alleviates chronic joint discomfort and improves mobility. - Ankylosing spondylitis: diminishes spinal inflammation and associated pain. - Acute pain: provides rapid relief of short‑term moderate pain from injury or surgery.

Meloxicam may cause a range of adverse reactions, most of which are dose‑related and reversible upon discontinuation.

Common Side Effects: - Gastrointestinal discomfort: nausea, dyspepsia or abdominal pain. - Headache: mild to moderate intensity. - Dizziness or vertigo. - Peripheral oedema: mild swelling of the lower limbs.

Serious or Rare Side Effects: - Gastrointestinal ulceration or bleeding. - Hepatic dysfunction: elevated liver enzymes or hepatitis. - Renal impairment: reduced kidney function or acute renal failure. - Cardiovascular events: increased risk of myocardial infarction or stroke, especially with long‑term use.

Before initiating therapy, consider the following safety measures. - Renal function: assess baseline kidney function and monitor periodically. - Hepatic health: evaluate liver enzymes prior to treatment and during prolonged use. - Cardiovascular risk: avoid in patients with established coronary artery disease unless benefits outweigh risks. - Concomitant NSAIDs or anticoagulants: use with caution to minimise bleeding risk. - Store at ambient temperature: keep below 25 °C, retain in original packaging, and protect from moisture.

Meloxicam can interact with several drug classes, altering efficacy or safety.

Major Interactions (Avoid): - Anticoagulants (e.g., warfarin): increased bleeding risk. - Other NSAIDs or COX‑2 inhibitors: heightened gastrointestinal toxicity. - Lithium: elevated lithium serum concentrations. - Methotrexate: potential for enhanced toxicity.

Moderate Interactions (Monitor Closely): - ACE inhibitors or ARBs: possible reduction in renal function. - Diuretics: may exacerbate fluid retention and renal effects. - Selective serotonin reuptake inhibitors (SSRIs): increased risk of gastrointestinal bleeding.